AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib in Vitiligo
If approved, upadacitinib will be the first systemic medication available for patients with vitiligo, according to the company.
If approved, upadacitinib will be the first systemic medication available for patients with vitiligo, according to the company.
Research published in the Journal of Cosmetic Dermatology highlights the stability and skin-mimicking properties of lipid-soluble vitamin C derivatives.